NasdaqGS:SYREBiotechs
Spyre Therapeutics (SYRE) Valuation After New Trial Milestones And Commercial Leadership Appointment
Spyre Therapeutics (SYRE) is back on investor radar after management outlined six planned proof of concept readouts for 2026 and reported faster enrollment in its SKYLINE ulcerative colitis trial, alongside appointing experienced commercial leader Kate Tansey Chevlen as CCO.
See our latest analysis for Spyre Therapeutics.
The share price has reacted quickly to the clinical and leadership updates, with a 1-day share price return of 7.15% and a 90-day share price return of 47.81%. The 1-year...